Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 ± 0.25 to 0.50 ± 0.18 and 0.29 ± 0.19logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 ± 65 to 208 ± 23 μm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC.
Abstract
In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 ± 0.25 to 0.50 ± 0.18 and 0.29 ± 0.19logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 ± 65 to 208 ± 23 μm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC.
참고문헌 (13)
- Wang M, "Central serous chorioretinopathy", Acta Ophthalmol, 86, pp.126~145 (2008)
- Marmor MF, "Central serous chorioretinopathy: bilateralmultifocal electroretinographic abnormalities", ArchOphthalmol, 117, pp.184~188 (1999)
- Burumcek E, "Laserphotocoagulation for persistent central serous retinopathy:results of long-term follow-up", Ophthalmology, 104, pp.616~622 (1997)
- Spitznas M, "Pathogenesis of central serous retinopathy: anew working hypothesis", Graefes Arch Clin Exp Ophthalmol, 224, pp.321~324 (1986)
- Marmor MF, "New hypotheses on the pathogenesis andtreatment of serous retinal detachment", Graefes Arch ClinExp Ophthalmol, 226, pp.548~552 (1988)
- Cardillo Piccolino F, "Photodynamictherapy for chronic central serous chorioretinopathy", Retina, 23, pp.752~763 (2003)
- Torres-Soriano ME, "A pilot study of intravitreal bevacizumab for the treatmentof central serous chorioretinopathy (case reports)", GraefesArch Clin Exp Ophthalmol, 246, pp.1235~1239 (2008)
- Von Graefe A, "Ueber centrale recidivierende retinitis", Graefes Arch Clin Exp Ophthalmol, 12, pp.211~215 (1866)
- Schaal KB, "Intravitreal bevacizumabfor treatment of chronic central serous chorioretinopathy", Eur J Ophthalmol, 19, pp.613~617 (2009)
- Chan WM, "Choroidal vascularremodelling in central serous chorioretinopathy after indocyaninegreen guided photodynamic therapy with verteporfin:a novel treatment at the primary disease level", Br JOphthalmol, 87, pp.1453~1458 (2003)
- Battaglia Parodi M, "Photodynamictherapy in chronic central serous chorioretinopathy", Retina, 23, pp.235~237 (2003)
- Ober MD, "Photodynamictherapy for focal retinal pigment epithelial leaks secondaryto central serous chorioretinopathy", Ophthalmology, 112, pp.2088~2094 (2005)
- Colucciello M, "Choroidal neovascularization complicatingphotodynamic therapy for central serous retinopathy", Retina, 26, pp.239~242 (2006)